Zobrazeno 1 - 10
of 397
pro vyhledávání: '"Cynthia X, Ma"'
Autor:
Xiuli Zhang, S. Peter Goedegebuure, Michael Y. Chen, Rashmi Mishra, Felicia Zhang, Yik Yeung Yu, Kartik Singhal, Lijin Li, Feng Gao, Nancy B. Myers, Tammi Vickery, Jasreet Hundal, Michael D. McLellan, Mark A. Sturmoski, Samuel W. Kim, Ina Chen, Jesse T. Davidson, Narendra V. Sankpal, Stephanie Myles, Rama Suresh, Cynthia X. Ma, Ademuyiwa Foluso, Andrea Wang-Gillam, Sherri Davies, Ian S. Hagemann, Elaine R. Mardis, Obi Griffith, Malachi Griffith, Christopher A. Miller, Ted H. Hansen, Timothy P. Fleming, Robert D. Schreiber, William E. Gillanders
Publikováno v:
Genome Medicine, Vol 16, Iss 1, Pp 1-17 (2024)
Abstract Background Neoantigen vaccines can induce or enhance highly specific antitumor immune responses with minimal risk of autoimmunity. We have developed a neoantigen DNA vaccine platform capable of efficiently presenting both HLA class I and II
Externí odkaz:
https://doaj.org/article/361f87535f3347da8e2cfda87d75ab59
Autor:
Yi Zhang, Shuyan Zhou, Yan Kai, Ya-qin Zhang, Changmin Peng, Zhuqing Li, Muhammad Jameel mughal, Belmar Julie, Xiaoyan Zheng, Junfeng Ma, Cynthia X. Ma, Min Shen, Matthew D. Hall, Shunqiang Li, Wenge Zhu
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-17 (2024)
Abstract Cyclin-dependent kinases 4 and 6 (CDK4/6) play a pivotal role in cell cycle and cancer development. Targeting CDK4/6 has demonstrated promising effects against breast cancer. However, resistance to CDK4/6 inhibitors (CDK4/6i), such as palboc
Externí odkaz:
https://doaj.org/article/9b3874667b074c8ea342ac7c3e37c941
Autor:
Lorenzo Gerratana, Andrew A. Davis, Marko Velimirovic, Katherine Clifton, Whitney L. Hensing, Ami N. Shah, Charles S. Dai, Carolina Reduzzi, Paolo D’Amico, Firas Wehbe, Arielle Medford, Seth A. Wander, William J. Gradishar, Amir Behdad, Fabio Puglisi, Cynthia X. Ma, Aditya Bardia, Massimo Cristofanilli
Publikováno v:
Breast Cancer Research, Vol 25, Iss 1, Pp 1-12 (2023)
Abstract Background although being central for the biology and druggability of hormone-receptor positive, HER2 negative metastatic breast cancer (MBC), ESR1 and PIK3CA mutations are simplistically dichotomized as mutated or wild type in current clini
Externí odkaz:
https://doaj.org/article/e709c732d873422f9a1a421cdc570023
Autor:
Donna M. Peehl, Cristian T. Badea, Thomas L. Chenevert, Heike E. Daldrup-Link, Li Ding, Lacey E. Dobrolecki, A. McGarry Houghton, Paul E. Kinahan, John Kurhanewicz, Michael T. Lewis, Shunqiang Li, Gary D. Luker, Cynthia X. Ma, H. Charles Manning, Yvonne M. Mowery, Peter J. O'Dwyer, Robia G. Pautler, Mark A. Rosen, Raheleh Roudi, Brian D. Ross, Kooresh I. Shoghi, Renuka Sriram, Moshe Talpaz, Richard L. Wahl, Rong Zhou
Publikováno v:
Tomography, Vol 9, Iss 2, Pp 657-680 (2023)
The availability of high-fidelity animal models for oncology research has grown enormously in recent years, enabling preclinical studies relevant to prevention, diagnosis, and treatment of cancer to be undertaken. This has led to increased opportunit
Externí odkaz:
https://doaj.org/article/315dd791b13b4c40966ef7abc8d61d4c
Autor:
Foluso O. Ademuyiwa, Donald W. Northfelt, Tracey O’Connor, Ellis Levine, Jingqin Luo, Yu Tao, Jeremy Hoog, Marie L. Laury, Tracy Summa, Trish Hammerschmidt, Zhanfang Guo, Ashley Frith, Katherine Weilbaecher, Mateusz Opyrchal, Rebecca Aft, Katherine Clifton, Rama Suresh, Nusayba Bagegni, Ian S. Hagemann, Michael D. Iglesia, Cynthia X. Ma
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-9 (2023)
Abstract Patients with ER+/HER2+ breast cancer (BC) are less likely to achieve pathological complete response (pCR) after chemotherapy with dual HER2 blockade than ER−/HER2+ BC. Endocrine therapy plus trastuzumab is effective in advanced ER+/HER2+
Externí odkaz:
https://doaj.org/article/49d5c74d8dba4b95b0b0ea0d7e2de4d4
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-16 (2022)
Kinases are important drug targets, but predicting their activities from phosphoproteomics data remains challenging. While many existing prediction tools rely on phosphosite-specific quantitative data, Crowl et al. develop a kinase activity predictio
Externí odkaz:
https://doaj.org/article/17765b6e09df4c2d805f950c93df9c4b
Autor:
Jairam Krishnamurthy, Jingqin Luo, Rama Suresh, Foluso Ademuyiwa, Caron Rigden, Timothy Rearden, Katherine Clifton, Katherine Weilbaecher, Ashley Frith, Anna Roshal, Pavan K. Tandra, Mathew Cherian, Tracy Summa, Brittney Haas, Shana Thomas, Leonel Hernandez-Aya, Mattias Bergqvist, Lindsey Peterson, Cynthia X. Ma
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-7 (2022)
Abstract Palbociclib 3-weeks-on/1-week-off, combined with hormonal therapy, is approved for hormone receptor positive (HR+)/HER2-negative (HER2−) advanced/metastatic breast cancer (MBC). Neutropenia is the most frequent adverse event (AE). We aim t
Externí odkaz:
https://doaj.org/article/66f1f8841c624feda0766f004e302bc2
Autor:
Andrew A. Davis, Lorenzo Gerratana, Katherine Clifton, Arielle J. Medford, Marko Velimirovic, Whitney L. Hensing, Leslie Bucheit, Ami N. Shah, Paolo D'Amico, Carolina Reduzzi, Qiang Zhang, Charles S. Dai, Elyssa N. Denault, Nusayba A. Bagegni, Mateusz Opyrchal, Foluso O. Ademuyiwa, Ron Bose, William J. Gradishar, Amir Behdad, Cynthia X. Ma, Aditya Bardia, Massimo Cristofanilli
Publikováno v:
EBioMedicine, Vol 86, Iss , Pp 104316- (2022)
Summary: Background: Limited data exist to characterise molecular differences in circulating tumour DNA (ctDNA) for patients with invasive lobular carcinoma (ILC). We analysed metastatic breast cancer patients with ctDNA testing to assess genomic dif
Externí odkaz:
https://doaj.org/article/07b125b3c92b42acba72a92a3f8e5d48
Autor:
Hua Sun, Song Cao, R. Jay Mashl, Chia-Kuei Mo, Simone Zaccaria, Michael C. Wendl, Sherri R. Davies, Matthew H. Bailey, Tina M. Primeau, Jeremy Hoog, Jacqueline L. Mudd, Dennis A. Dean, Rajesh Patidar, Li Chen, Matthew A. Wyczalkowski, Reyka G. Jayasinghe, Fernanda Martins Rodrigues, Nadezhda V. Terekhanova, Yize Li, Kian-Huat Lim, Andrea Wang-Gillam, Brian A. Van Tine, Cynthia X. Ma, Rebecca Aft, Katherine C. Fuh, Julie K. Schwarz, Jose P. Zevallos, Sidharth V. Puram, John F. Dipersio, The NCI PDXNet Consortium, Brandi Davis-Dusenbery, Matthew J. Ellis, Michael T. Lewis, Michael A. Davies, Meenhard Herlyn, Bingliang Fang, Jack A. Roth, Alana L. Welm, Bryan E. Welm, Funda Meric-Bernstam, Feng Chen, Ryan C. Fields, Shunqiang Li, Ramaswamy Govindan, James H. Doroshow, Jeffrey A. Moscow, Yvonne A. Evrard, Jeffrey H. Chuang, Benjamin J. Raphael, Li Ding
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-20 (2021)
Patient-derived xenograft models (PDX) have been extensively used to study the molecular and clinical features of cancers. Here the authors present a cohort of 536 PDX models from 25 cancers, as well as their genomic and evolutionary profiles and the
Externí odkaz:
https://doaj.org/article/e6286532f9bc487a87943a142621d7a3
Autor:
Maitri Kalra, Yan Tong, David R. Jones, Tom Walsh, Michael A. Danso, Cynthia X. Ma, Paula Silverman, Mary-Claire King, Sunil S. Badve, Susan M. Perkins, Kathy D. Miller
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-7 (2021)
Abstract Patients with triple-negative breast cancer (TNBC) who have residual disease after neoadjuvant therapy have a high risk of recurrence. We tested the impact of DNA-damaging chemotherapy alone or with PARP inhibition in this high-risk populati
Externí odkaz:
https://doaj.org/article/5b3db53e4cb24f2c9c8cea80e9eb7951